CStone Pharmaceuticals’ exclusive collaboration and license agreement with Blueprint Medicines

Cooley advised CStone Pharmaceuticals on its exclusive collaboration and license agreement with Blueprint Medicines to develop and commercialize its cancer therapy, avapritnib, in mainland China, Hong…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Avatar

Author: Michael Patrini

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here